Identifying and treating ROBO1-ve /DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients.
Marina G FerrariArsheed A GanaieAshraf ShabenahAdrian P MansiniLi WangPaari MuruganElai DavicioniJinhua WangYibin DengLuke H HoeppnerChristopher A WarlickBadrinath R KonetyMohammad SaleemPublished in: The Prostate (2020)
We suggest that ROBO1 status forms as predictive biomarker of outcome in high-risk populations such as African-Americans and DOCK1-targeting therapy has a clinical potential for treating metastatic-CaP.